NCT03686488 2026-03-02
TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
Clinical Trials
243 trialsNCT05641896 2026-01-22
18F-FAPI-74 GI
SOFIE
Phase 2 Completed
NCT04505553 2026-01-21
Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer
University of Washington
Phase 2 Completed
NCT05419362 2025-12-16
GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer
Genome & Company
Phase 2 Completed
NCT04798781 2025-12-11
Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma
Cedars-Sinai Medical Center
Phase 2 Completed
NCT01191697 2025-11-03
CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT04768686 2025-09-25
FLX475 Combined With Pembrolizumab in Patients With Advanced or Metastatic Gastric Cancer
Hanmi Pharmaceutical Company Limited
Phase 2 Completed
NCT05104567 2025-09-24
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
Sanofi
Phase 2 Completed
NCT03929666 2025-09-12
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Jazz Pharmaceuticals
Phase 2 Completed
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT02205047 2025-07-31
INNOVATION
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT03636893 2025-07-23
Dragon III: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer
Ruijin Hospital
Phase 2 Completed
NCT02078700 2025-06-25
Feasibility of an Early Palliative Care Intervention for Metastatic Cancer Patients. A Phase 2 Study.
Azienda USL Reggio Emilia - IRCCS
Phase 2 Completed
NCT06812403 2025-06-25
Combination COMBO Endoscopy Oropharyngeal Airway With High-Flow Nasal Cannula Oxygenation in Sedated Gastrointestinal Endoscopy for Obese Patients
Zhejiang University
Phase 2 Completed
NCT06804876 2025-05-21
COMBO Endoscopy Oropharyngeal Airway in Sedated Gastrointestinal Endoscopy for Obese Patients
Zhejiang University
Phase 2 Completed
NCT03050879 2025-04-24
ICGTinLG
Fujian Medical University
Phase 2 Completed
NCT03064490 2025-04-10
PROCEED
Duke University
Phase 2 Completed
NCT03627728 2025-03-13
a-MANTRA
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2 Completed
NCT03092518 2025-02-19
Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03662659 2025-02-05
An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers
Bristol-Myers Squibb
Phase 2 Completed
NCT04034251 2025-02-03
Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT04535414 2025-01-17
Phase II Randomized Trial of Bethesda Protocol Compared to Cambridge Method for Detection of Early Stage Gastric Cancer in CDH1 Mutation Carriers
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00780494 2025-01-14
Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma
Stanford University
Phase 2 Completed
NCT01876927 2025-01-09
GastroDOC
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Completed
NCT01286766 2024-12-27
Neoadjuvant Combination Chemotherapy of DCS and DCF in Patients With Locally Advanced Gastric Adenocarcinoma
Yonsei University
Phase 2 Completed
NCT03878472 2024-12-16
Neoadjuvant Immunotherapy for Resectable Gastric Cancer
Qilu Hospital of Shandong University
Phase 2 Completed
NCT04989816 2024-11-21
DG-06
AstraZeneca
Phase 2 Completed
NCT04871204 2024-10-31
OTIS
Karolinska University Hospital
Phase 2 Completed
NCT03427814 2024-10-26
Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer
BeiGene
Phase 2 Completed
NCT02040142 2024-10-24
HIPEC for Peritoneal Carcinomatosis
Albert Einstein College of Medicine
Phase 2 Completed
NCT03469557 2024-10-23
BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma
BeiGene
Phase 2 Completed
NCT03382600 2024-06-11
KEYNOTE-659
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT04547153 2024-03-25
Infusional Fluorouracil and Weekly Docetaxel for Gastric Cancer With Bone Marrow Involvement and DIC
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2 Completed
NCT03694522 2024-02-28
FIGHT
Five Prime Therapeutics, Inc.
Phase 2 Completed
NCT02918162 2024-02-15
Perioperative Chemo and Pembrolizumab in Gastric Cancer
Columbia University
Phase 2 Completed
NCT03549494 2024-02-07
Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction
Catalysis SL
Phase 2 Completed
NCT04694183 2024-02-07
The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer
The First Hospital of Jilin University
Phase 2 Completed
NCT03283761 2024-02-06
FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma
Big Ten Cancer Research Consortium
Phase 2 Completed
NCT04770623 2024-01-30
Docetaxel and Irinotecan in Gastric Cancer
Menoufia University
Phase 2 Completed
NCT03196232 2024-01-23
Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer
Stanford University
Phase 2 Completed
NCT03472365 2024-01-11
A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT01522768 2023-11-01
Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02555358 2023-10-19
Three Drugs in Advanced Gastric Cancer Neoadjuvant Chemotherapy for Stage â…¢ Clinical Study
Hebei Medical University
Phase 2 Completed
NCT01063517 2023-07-20
Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients
AstraZeneca
Phase 2 Completed
NCT00003298 2023-07-06
Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00033657 2023-06-28
Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00003237 2023-06-22
Combination Chemotherapy After Surgery in Treating Patients With Cancer of the Esophagus or Stomach
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT02954536 2023-03-16
Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT04099641 2023-02-08
An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients
OncXerna Theraputics, Inc.
Phase 2 Completed
NCT02501603 2023-01-27
Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer
Yonsei University
Phase 2 Completed